Vertex Pharmaceuticals/$VRTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Vertex Pharmaceuticals
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Ticker
$VRTX
Sector
Primary listing
Employees
6,400
Headquarters
Website
VRTX Metrics
BasicAdvanced
$114bn
26.71
$16.86
0.30
-
Price and volume
Market cap
$114bn
Beta
0.3
52-week high
$507.92
52-week low
$362.50
Average daily volume
1.1m
Financial strength
Current ratio
3.023
Quick ratio
2.382
Long term debt to equity
10.26
Total debt to equity
10.26
Interest coverage (TTM)
360.53%
Profitability
EBITDA (TTM)
4,969.95
Gross margin (TTM)
54.39%
Net profit margin (TTM)
35.51%
Operating margin (TTM)
39.25%
Effective tax rate (TTM)
16.02%
Revenue per employee (TTM)
$1,910,000
Management effectiveness
Return on assets (TTM)
12.14%
Return on equity (TTM)
24.20%
Valuation
Price to earnings (TTM)
26.713
Price to revenue (TTM)
9.4
Price to book
5.91
Price to tangible book (TTM)
6.41
Price to free cash flow (TTM)
30.956
Free cash flow yield (TTM)
3.23%
Free cash flow per share (TTM)
14.55
Growth
Revenue change (TTM)
10.07%
Earnings per share change (TTM)
-538.91%
3-year revenue growth (CAGR)
9.89%
10-year revenue growth (CAGR)
25.19%
3-year earnings per share growth (CAGR)
10.35%
10-year earnings per share growth (CAGR)
26.16%
What the Analysts think about VRTX
Analyst ratings (Buy, Hold, Sell) for Vertex Pharmaceuticals stock.
VRTX Financial Performance
Revenues and expenses
VRTX Earnings Performance
Company profitability
VRTX News
AllArticlesVideos
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany
Business Wire·1 week ago
These Analysts Revise Their Forecasts On Vertex Pharmaceuticals After Q1 Earnings
Benzinga·1 week ago
Vertex Reports First Quarter 2026 Financial Results
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Vertex Pharmaceuticals stock?
Vertex Pharmaceuticals (VRTX) has a market cap of $114B as of May 15, 2026.
What is the P/E ratio for Vertex Pharmaceuticals stock?
The price to earnings (P/E) ratio for Vertex Pharmaceuticals (VRTX) stock is 26.71 as of May 15, 2026.
Does Vertex Pharmaceuticals stock pay dividends?
No, Vertex Pharmaceuticals (VRTX) stock does not pay dividends to its shareholders as of May 15, 2026.
When is the next Vertex Pharmaceuticals dividend payment date?
Vertex Pharmaceuticals (VRTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Vertex Pharmaceuticals?
Vertex Pharmaceuticals (VRTX) has a beta rating of 0.3. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.